Aussie study offers new MIGS head-to-head comparison

Australian ophthalmologists have published the first independent head-to-head comparison of two leading minimally invasive glaucoma surgery (MIGS) devices, finding no significant difference in intraocular pressure (IOP) outcomes but a potential greater reduction in medication use in one group. Read more

Nova Eye Medical touts new MIGS improvements in latest financials

 

Despite modest sales growth in the first half of the current financial year, ASX-listed Nova Eye Medical believes it’s poised for stronger returns from its glaucoma portfolio with a revamped canaloplasty device, making the technology more accessible to a broader base of ophthalmologists. Read more

Dr David Lubeck

It’s all about the (aqueous) flow

When it comes to the treatment of glaucoma, there is growing evidence to suggest that the ability to re-establish the natural flow of aqueous humour plays a critical role not only in reducing IOP, but also in preserving the health of the corneal endothelium, says US ophthalmologist DR DAVID LUBECK.

Read more

Itrack-operation Nova eye medical

Reaching new depths with iTrack


MIGS has triggered a shift in the glaucoma paradigm, enabling surgical intervention that bridges the gap between medical management and invasive surgery. While much of the focus has been on stent-based procedures, DR NATHAN KERR says surgeons should be excited by an entirely different approach by Australia’s Nova Eye Medical.

Read more

© All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

JOIN OUR NEWSLETTER

JOIN OUR NEWSLETTER
Close